Abstract
Over the past decade there has been a revolution in the prospects for vaccination against many of the infectious agents that still produce massive mortality and morbidity around the world. The reason for this revolution is the potential of a new technology, molecular biology, applied to the vaccine field, as evidenced by most of the chapters of this volume. However, with very few exceptions this increased potential for vaccination against these diseases has not yet been translated into reality. One of the reasons for this is that the novel recombinant proteins, with all their inherent advantages of safety and defined composition, often also have the disadvantage of lower immunogenicity than whole killed or live vaccines (Allison, 1983). Because of this, there is now a lot of work being done on novel means of enhancing vaccine immunogenicity. This search includes a variety of materials of various origins, including synthetic (Chapters 11 and 20), bacterial (Chapters 12 and 21), and plant (Chapters 22 and 23). This chapter, along with chapters by Lachman et al. (Chapter 29) and Dong et al. (Chapter 27), focuses on the use of naturally occurring cytokines as immunological adjuvants.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Abraham, E., and Shah, S., 1992, Intranasal immunization with liposomes containing IL-2 enhances bacterial Polysaccharide antigen-specific pulmonary secretory antibody response, J. Immunol. 149:3719–3726.
Afonso, L. C. C., Scharton, T. M., Viera, L. Q., Wysocka, M., Trinchieri, G., and Scott, P., 1994, The adjuvant effect of interleukin-12 in a vaccine against Leishmania major, Science 263:235–237.
Allison, A. C., 1983, Immunological adjuvants and their mode of action, in: New Approaches to Vaccine Development (R. Bell and G. Torrigiani, eds.), WHO, Schwabe & CoAG, Basel, pp. 133–154.
Anderson, G., Urbano, O., Fedorka-Cray, P., Newell, A., Nunberg, J., and Doyle, M, 1987, Interleukin-2 and protective immunity in Haemophilus pleuropneumoniae. Preliminary studies, in: Vaccines’ 87, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 22–25.
Anderson, K. P., Fennie, E. H., and Yilma, T., 1989, Enhancement of a secondary antibody response to vesicular stomatitis virus “G” protein by IFNg treatment at primary immunization, J. Immunol. 140:3599–3604.
Antoni, G., Presentini, F., Perm, A., Tagliabue, A., Ghiara, P., Censini, S., Volpini, L., Villa, L., and Boraschi, D., 1986, A short synthetic peptide fragment of human IL-1 with immunostimulatory but not inflammatory activity, J. Immunol. 137:3201–3204.
Biozzi, G., Stiffel, C., Mouton, D., and Bouthillier, Y., 1975, Selection of lines of mice with high and low antibody responses to complex immunogens, in: Immunogenetics and Immunodeficiency (B. Benacerraf, ed.), MTP Press, Lancaster, p. 179–201.
Boraschi, D., Villa, L., Volpini, G., Bossu, P., Censini, S., Ghiara, P., Scapigliat, G., Nencioni, L., Bartalini, M., Matteucci, G., Cioli, F., Carnasciali, M., Olmastroni, E., Mengozzi, M., Ghezzi, P., and Tagliabue, A., 1990, Differential activity of interleukin-la and interleukin-1β in the stimulation of immune responses in vivo, Eur. J. Immunol. 20:317–321.
Carrier, M. J., Chatfield, S. N., Dougan, G., Nowicka, U. T. A., O’Callaghan, D., Beesley, J. E., Milano, S., Cillari, E., and Liew, F. Y, 1992, Expression of human IL-1β in Salmonella typhimurium: A model system for the delivery of therapeutic proteins in vivo, J. Immunol. 148:1176–1182.
Chan, S. H., Perussia, B., Gupta, J. W., Kobayashi, M., Pospisil, M., Young, H. A., Wolf, S. F, Young, D., Clark, S. G, and Trinchieri, G., 1991, Induction of IFNg production by natural killer cell stimulatory factor: Characterization of the responder cells and synergy with other inducers, J. Exp. Med. 173:869–879.
Clemens, M. J., Morris, A. G., and Gearing, A. J. H., 1987, Lymphokines and Interferons: A Practical Approach, IRL Press, Oxford.
Coffman, R. L., Seymour, B. W. P., Lebman, D. A., Hiraki, D. A., Christiansen, J. A., Shrader, B., Cherwinski, H. M., Savelkoul, H. F J., Finkelman, F. D., Bond, M. W., and Mosmann, T. R., 1988, The role of helper T cell products in mouse B cell differentiation and isotype regulation, Immunol. Rev. 102:5–26.
Denich, K., Borlin, P., O’Hanley, P., Howard, M. C., and Heath, A. W., 1993, The effects of expression of murine interleukin-4 by Aro A-Salmonella typhimurium: Persistence, immune response and the inhibition of macrophage killing, Infect. Immun. 61:4818–4827.
Ellouz, F., Adam, A., Cirorbaru, R., and Lederer, E., 1974, Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives, Biochem. Biophys. Res. Commun. 59:1317–1325.
Feng, G. S., Gray, P., Shepard, H. M., and Taylor, M. W., 1988, Antiproliferative activity of a hybrid protein between interferon γ and tumor necrosis factor β, Science 241:1501–1503.
Flexner, C., Hugin, A., and Moss, B., 1987, Prevention of vaccinia virus infection in immunodeficient mice by vector-directed IL-2 expression, Nature 330:259–261.
Frasca, D., Boraschi, D., Baschieri, S., Bossu, P., Tagliabue, A., Adorini, L., and Doria, G., 1989, In vivo restoration of T cell functions by human IL-1β or its 163–171 nonapeptide in immunodepressed mice, J. Immunol. 141:2651–2655.
Gajewski, T. F., and Fitch, F. W., 1988, Anti-proliferative effect of interferon gamma in immune regulation. 1. Interferon gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones, J. Immunol. 140:4245–4252.
Gerrard, T. L., Siegel, J. P., Dyer, D. R., and Zoon, K., 1987, Differential effects of interferon alpha and interferon gamma on IL-1 secretion by monocytes, J. Immunol. 138:2535–2540.
Ghiara, P., Boraschi, D., Nencioni, L., Ghezzi, P., and Tagliabue, A., 1987, Enhancement of in vivo immune response by tumor necrosis factor, J. Immunol. 139:3676–3679.
Good, M. F., Pombo, D., Lunde, M. N., Maloy, W. L., Halenbeck, R., Koths, K., Miller, L. H., and Berzofsky, J. A., 1988, Recombinant human IL-2 overcomes genetic nonresponsiveness to malaria sporozoite Peptides, J. Immunol. 141:972–977.
Grun, J. L., and Maurer, P. H., 1989, Different T helper subsets elicited in mice utilizing two different adjuvant vehicles; the role of endogenous interleukin in proliferative responses, Cell Immunol. 121:134–145.
Hazama, M., Mayumi-Aono, A., Miyazaki, T., Hinuma, S., and Fujisawa, Y., 1993a, Intranasal immunization against herpes simplex virus infection by using a recombinant glycoprotein D fused with immunomodulating proteins, the B subunit of Escherichia coli heat labile enterotoxin and interleukin-2, Immunology 78:643–649.
Hazama, M., Mayumi-Aono, A., Asakawa, N., Kuroda, S., Hinuma, S., and Fujisawa, Y., 1993b, Adjuvant independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin 2, Vaccine 11:629–636.
Heath, A. W., and Playfair, J. H. L., 1990, Conjugation of interferon gamma to antigen enhances its adjuvanticity, Immunology 71:454–456.
Heath, A. W., and Playfair, J. H. L., 1991, Early administration of interferon gamma as an adjuvant; an effect on a T helper subpopulation, in: Vaccines’ 91 (R. M. Chanock, H. S. Ginsberg, F. Brown, and R. A. Lerner, eds.), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 351–354.
Heath, A. W., and Playfair, J. H. L., 1992, Gamma interferon as an adjuvant for vaccines, in: Anti-infective Applications of Interferon Gamma (H. S. Jaffe, L. R. Bucalo, and S. A. Sherwin, eds.), Dekker, New York.
Heath, A. W., and Playfair, J. H. L., 1993, Cytokines as immunological adjuvants, Vaccine 7:427–434.
Heath, A. W., Devey, M. E., Brown, I. N., Richards, C. E., and Playfair, J. H. L., 1989a, Interferon gamma as an adjuvant in immunocompromised mice, Immunology 67:520–524.
Heath, A. W., Haque, N. A., DeSouza, J. B., and Playfair, J. H. L., 1989b, Interferon gamma as an effective immunological adjuvant, in: Vaccines’ 89, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, pp. 43–46.
Heath, A. W., Nyan, O., Richards, C. E., and Playfair, J. H. L., 1991, Effects of interferon gamma and saponin on lymphocyte traffic are inversely related to adjuvanticity and MHC class II expression, Int. Immunol. 3:285–291
Heinzel, F. P., Scoenhaut, D. S., Rerko, R. M., Rosser, L. E., and Gately, M. K., 1993, Recombinant interleukin 12 cures mice infected with Leishmania major, J. Exp. Med. 177:1505–1509.
Ho, R. J. Y., Burke, R. L., and Merigan, T. C., 1992, Liposome formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein D for the treatment of recurrent genital HSV-2 in guinea-pigs, Vaccine 10:209–213.
Hsieh, C.-S., Macatonia, S. E., Tripp, C. S., Wolf, S. F., O’Garra, A., and Murphy, K. M., 1993, Development of Thl CD4+ T cells through IL-12 produced by Listeria-induced macrophages, Science 260:547–549.
Hughes, H. P. A., and Babiuk, L. A., 1992, The adjuvant potential of cytokines, Biotechnol. Ther. 3:101–117.
Hughes, H. P. A., Campos, M., van Drunen Little-van den Hurk, S., Zamb, T., Sordillo, L. M., Godson, D., and Babiuk, L. A., 1992, Multiple administration of interleukin-2 potentiates antigen-specific responses to subunit vaccination with bovine herpesvirus-1 glycoprotein IV, Vaccine 10:226–230.
Katz, D., and Steward, M. W., 1975, The genetic control of antibody affinity in mice, Immunology 29:543.
Kawamura, H., Rosenberg, S., and Berzofsky, J. A., 1985, Immunization with antigen and interleukin-2 in vivo overcomes Ir gene low responsiveness, J. Exp. Med. 162:381–386.
Kimoto, M., Kindler, K., Higaki, M., Ody, C., Izui, S., and Vassail, P., 1988, Recombinant murine IL-3 fails to stimulate T or B lymphopoiesis in vivo, but enhances immune responses to T dependent antigens, J. Immunol. 140:1889–1894.
Locksley, R. M., and Scott, P., 1991, Helper T cell subsets in mouse leishmaniasis: Induction, expansion and effector function, Immunol. Today 12:A58–A61.
McCullough, K. C., Pullen, L., and Parkinson, D., 1991, The immune response against foot-and-mouth disease virus: Influence of the T lymphocyte growth factors IL-1 and IL-2 on the murine humoral response in vivo, Immunol. Lett. 31:41–46.
McCune, C. S., and Marquis, D. M., 1990, Interleukin-1 as an adjuvant for active specific immunotherapy in a murine tumor model, Cancer Res. 50:1212–1215.
Mbawuike, I. N., Wyde, P. R., and Anderson, P. M., 1990, Enhancement of the protective efficacy of inactivated influenza A virus vaccine in aged mice by IL-2-liposomes, Vaccine 8:347–352.
Merser, C., Sinay, P., and Adam, A., 1975, Total synthesis and adjuvant activity of bacterial peptidoglycan derivatives, Biochem. Biophys. Res. Commun. 66:1316–1322.
Meuer, S. C., Dumann, H., Meyer zum Buschenfelde, K. H., and Kohler, H., 1989, Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination, Lancet 1:15–17.
Mosmann, T. R., and Coffman, R. L., 1989, Different patterns of lymphokine secretion lead to different functional properties, Annu. Rev. Immunol. 7:145–173.
Nakai, S., Kawai, K., Hirai, T., and Tasaka, K., 1990, A mutant protein of human interleukin-1 beta with immunostimulatory but not pyrogenic potency, Life Sci. 47:1707–1714.
Nencioni, L., Villa, L., Tagliabue, A., Antoni, G., Presentini, R., Perin, F., Silvestre, S., and Boraschi, D., 1987, In vivo immunostimulating activity of the 163–171 peptide of human IL-1β, J. Immunol. 139:800–804.
Nunberg, J., Doyle, M. V, York, S. M., and York, C. J., 1989, Interleukin-2 acts as an adjuvant to enhance the potency of inactivated rabies virus vaccine, Proc. Natl. Acad. Sci. USA 86:4240–4243.
Odean, M. J., Frane, C. M., Van der Vieren, M., Tomai, M. A., and Johnson, A. G., 1990, Involvement of gamma interferon in antibody enhancement by adjuvants, Infect. Immun. 58:427–432.
Parish, C. R., and Liew, F. Y., 1972, Immune response to chemically modified flagellin. 3. Enhanced cell-mediated immunity during high and low zone antibody tolerance to flagellin, J. Exp. Med. 135:298–311.
Playfair, J. H. L., and DeSouza, J. B., 1987, Recombinant gamma interferon is a potent adjuvant for a malaria vaccine in mice, Clin. Exp. Immunol. 67:5–10.
Quiroga, J. A., Castillo, I., Porres, J. C., Casado, S., Saez, F., Gracia Martinez, M., Gomez, M., Inglada, L., Sanchez-Sicilia, L., Mora, A., et al., 1990, Recombinant gamma interferon as adjuvant to hepatitis B vaccine in haemodialysis patients, Hepatology 12:661–663.
Ramshaw, I. A., Andrew, M. E., Phillips, S. M. N., Boyle, D. B., and Coupar, B. E. H., 1987, Recovery of immunodeficient mice from a vaccinia virus/IL-2 recombinant infection, Nature 329:545–546.
Rao, K. V. S., and Nayak, A. R., 1990, Enhanced immunogenicity of a sequence derived from hepatitis B virus surface antigen in a composite peptide that includes the immunostimulatory region from human interleukin-1, Proc. Natl. Acad. Sci. USA 87:5519–5522.
Reed, S. G., Pihl, D. K., Conlon, P. J., and Grabstein, K. H., 1989a, IL-1 as adjuvant. Role of T cells in the augmentation of specific antibody production by recombinant human IL-1a, J. Immunol. 142:3129–3133.
Reed, S. G., Pihl, D. K., and Grabstein, K. H., 1989b, Immune deficiency in chronic Trypanosoma cruzi infection. Recombinant IL-1 restores T helper function for antibody production, J. Immunol. 142:2067–2071.
Scott, P., Pearce, E., Cheever, A. W., Coffman, R. L., and Sher, A., 1989, Role of cytokines and CD4+ T cell subsets in the regulation of parasite immunity and disease, Immunol. Rev. 112:161–182.
Singh-Hora, M., Rana, R. K., Nunberg, J. H., Tice, T. R., Gilley, R. M., and Hudson, M. E., 1990, Controlled release of interleukin-2 from biodegradable microspheres, Biotechnology 8:755–758.
Staruch, M. J., and Wood, D. D., 1983, The adjuvanticity of interleukin-1 in vivo, J. Immunol. 130:2191–2194.
Sypek, J. P., Chung, C. L., Mayor, E. H., Subramanyam, J. M., Goldman, S. J., Sieburth, D. S., Wolf, S. F., and Schaub, R. G., 1993, Resolution of cutaneous leishmaniasis: Interleukin-12 initiates a protective T helper type 1 immune response, J. Exp. Med. 177:1797–1802.
Tagliabue, A., and Boraschi, D., 1993, Cytokines as vaccine adjuvants: Interleukin-1 and its synthetic peptide 163–171, Vaccine 11:594–595.
Takatsuki, F., Okano, A., Suzuki, C., Chieda, R., Takahara, Y., Hirano, T., Kishimoto, T., Hamuro, J., and Akiyama, Y., 1988, Human recombinant IL-6/B cell stimulatory factor 2 augments murine antigen specific antibody responses in vitro and in vivo, J. Immunol. 141:3072–3077.
Talmadge, J. E., Phillips, H., Schneider, M., Rowe, T., Pennington, R., Bowersox, O., and Lenz, B., 1988, Immunomodulatory properties of recombinant murine and human tumor necrosis factor, Cancer Res. 48:544–550.
Tao, M. H., and Levy, R., 1993, Idiotype GMCSF fusion protein as a vaccine for B cell lymphoma, Nature 362:755–758.
Weinberg, A., and Merigan, T. C., 1988, Recombinant interleukin-2 as an adjuvant for vaccine-induced protection. Immunization of guinea pigs with herpes simplex virus subunit vaccines, J. Immunol. 140:294–299.
Weyland, C., Goronzy, J., Fathman, C. G., and O’Hanley, P., 1987, Administration in vivo of recombinant interleukin-2 protects mice against septic death, J. Clin. Invest. 79:1756–1763.
Yin, T. G., Schendel, P., and Yang, Y. C., 1992, Enhancement of in vitro and in vivo antibody responses by interleukin-11, J. Exp. Med. 175:211–216.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer Science+Business Media New York
About this chapter
Cite this chapter
Heath, A.W. (1995). Cytokines as Immunological Adjuvants. In: Powell, M.F., Newman, M.J. (eds) Vaccine Design. Pharmaceutical Biotechnology, vol 6. Springer, Boston, MA. https://doi.org/10.1007/978-1-4615-1823-5_28
Download citation
DOI: https://doi.org/10.1007/978-1-4615-1823-5_28
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-5737-7
Online ISBN: 978-1-4615-1823-5
eBook Packages: Springer Book Archive